TAZRET
Manufacturer Details
GLENMARK
Compositions:
Tazarotene 0.05% w/w GEL,
Tazarotene 0.1% w/w CREAM,
|
Strength
|
Rate
|
Packing Style
|
|
0.05% gel
|
271.50
|
20g GEL
|
|
0.1% crm
|
386.50
|
20g CREAM
|
List of Related Indications:
List Of Drugs:
- Tazarotene- Retinoids- Dermatological-(FDC-List )- (Sept 2003)
Indication Type Description:
Drug Interaction:
Do not apply emolients or cosmetics within 1 hour
Indication:
New Drugs Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
Tazarotene Anti-Acne 12-09-2003
FIXED DOSE COMBINATIONS APPROVED BY DCG(I)
FROM JANUARY 1961 TILL NOVEMBER 2014
Name of Drug Indication Date of Approval
1.Tazrotene 0.05% + 24-05-2005
Mometasone Furoate 0.1% cream
Addl.stgth
For psorisis
2.Tazarotene 1mg + 04-01-2005
Mometasone Furoate 1mg per gm cream
For plaque psoriasis
Mild to moderate plaque psoriasis
Adverse Reaction:
Pruritus Burning Erythema Rash Irritation Desquamation Dermatitis
Skin pain Dry skin Skin discoloration Worsening of psoriasis
Withdraw if irritation occurs
Contra-Indications:
Pregnancy -
contraception must be used Lactation
Special precautions-
Perform reliable test to exclude pregnancy Contraception must be used Avoid skin folds, face and mouth, eyes, eyelids, scalp, inflammed skin and excess UV light Discontinue if sensitization occurs
Dosages/ Overdosage Etc:
Mild to moderate plaque psoriasis
Dosage-
Apply to affected area once daily in the evening usually for up to 12 weeks
Max 30g daily Not recommended for patients below 18 years
Pregnancy and lactation:
Caution -
Use contraindicated during Pregnancy and lactation Contraception must be used
